Ignite Creation Date:
2025-12-24 @ 10:32 PM
Ignite Modification Date:
2026-01-02 @ 10:03 AM
Study NCT ID:
NCT03881735
Status:
WITHDRAWN
Last Update Posted:
2021-03-10
First Post:
2019-03-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation
Sponsor:
Roswell Park Cancer Institute
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-12-02
Start Date Type:
ACTUAL
Primary Completion Date:
2021-11-19
Primary Completion Date Type:
ESTIMATED
Completion Date:
2022-11-19
Completion Date Type:
ESTIMATED
First Submit Date:
2019-03-15
First Submit QC Date:
None
Study First Post Date:
2019-03-19
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-03-08
Last Update Post Date:
2021-03-10
Last Update Post Date Type:
ACTUAL